Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist

Virchows Archiv

Volumn 465, Issue 6, 2014, Pages 623-628

  Montironi, Rodolfo ^a   Hammond, Elizabeth H ^b   Lin, Daniel W ^c   Gore, John L ^c   Srigley, John R ^d   Samaratunga, Hema ^e   Egevad, Lars ^f   Rubin, Mark A ^g   Nacey, John ^h   Klotz, Laurence ⁱ   Sandler, Howard ^j   Zietman, Anthony L ^k   Holden, Stuart ^l   Humphrey, Peter A ^m   Evans, Andrew J ⁿ   Delahunt, Brett ^h   McKenney, Jesse K ^o   Berney, Daniel ^p   Wheeler, Thomas M ^q   Chinnaiyan, Arul ^r   True, Lawrence ^s   Knudsen, Beatrice ^j   Epstein, Jonathan I ^t   Amin, Mahul B ^j   more..

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h UNIVERSITY OF OTAGO   (New Zealand)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY HEALTH NETWORK   (Canada)

^o LERNER RESEARCH INSTITUTE   (United States)

^p ROYAL LONDON HOSPITAL   (United Kingdom)

^q BAYLOR COLLEGE OF MEDICINE   (United States)

^r UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^s UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^t JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Accurate pathology reporting; Active surveillance; Localized prostate cancer; Low risk prostate cancer; Overtreatment

Indexed keywords

ACTIVE SURVEILLANCE; CANCER GRADING; CANCER GROWTH; CANCER LOCALIZATION; CONSENSUS; DISEASE SURVEILLANCE; GLEASON SCORE; HUMAN; INTRADUCTAL CARCINOMA; LYMPH VESSEL METASTASIS; MALE; MOLECULAR DIAGNOSIS; NEEDLE BIOPSY; PATHOLOGIST; PATIENT SELECTION; PERINEURAL INVASION; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SARCOMATOID CARCINOMA; SMALL CELL CARCINOMA; TUMOR VOLUME; CONSENSUS DEVELOPMENT; DISEASE COURSE; PATHOLOGY; PROSTATE TUMOR; STANDARDS; WATCHFUL WAITING;

DISEASE PROGRESSION; HUMANS; MALE; PATHOLOGY, CLINICAL; PATIENT SELECTION; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84914115404     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1668-5     Document Type: Review

References (25)

1. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR, Investigators CPSURE (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401
2. Albertsen PC, Hanley JA, Fine J (2005) 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101
3. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123
4. Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300–4305
5. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94:981–990
6. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. JAMA 291:2713–2719
7. McGregor M, Hanley JA, Boivin JF, McLean RG (1998) Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 159:1368–1372
8. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O’Leary M, Walker-Corkery E, Yao SL (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202–1209
9. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
10. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106–2131
11. Network NCC (2010) NCCN clinical practice guidelines in oncology: prostate cancer. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
12. Dall’Era MA, Cooperberg MR, Chan JM, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112:1650–1659
13. Xia J, Trock BJ, Cooperberg MR, Gulati R, Zeliadt SB, Gore JL, Lin DW, Carroll PR, Carter HB, Etzioni R (2012) Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res 18:5471–5478
14. Ganz PABJ, Burke W, Col NF, Corso PS, Dodson E, Hammond ME, Kogan BA, Lynch CF, Newcomer L, Seifter EJ, Tooze JA, Viswanath K, Wessells H (2011) National institutes of health state-of-the-science conference statement: role of active surveillance in the management of men with localized prostate cancer. NIH Consens State Sci Statement 28:1–27
15. Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, et al. (2014) The critical role of the pathologist in determining eligibility for active surveillance as a management options in patients with prostate cancer: consensus statement with recommendations supported by the college of american pathologist, international society of urologic pathologist, association of directors of anatomic and surgical pathology, the New Zealand society of pathologists and the prostate cancer foundation. Arch Pathol Lab Med
16. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ (2013) Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol 63:597–603
17. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131
18. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185–2190
19. Montironi R, Lopez-Beltran A, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L (2014) Contemporary update on pathology-related issues on routine workup of prostate biopsy: sectioning, tumor extent measurement, specimen orientation, and immunohistochemistry. Anal Quant Cytol Histol 36:61–70
20. Montironi R, Scarpelli M, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montorsi F (2012) Extent of cancer of less than 50 % in any prostate needle biopsy core: how many millimeters are there? Eur Urol 61:751–756
21. Brimo F, Vollmer RT, Corcos J, Kotar K, Begin RL, Humphrey PA, Bismar TA (2008) Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. Histopathology 53:177–183
22. Karram S, Trock BJ, Netto GJ, Epstein JI (2011) Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol 35:1351–1355
23. Schultz L, Maluf CE, da Silva RC, Falashi Rde H, da Costa MV, Schultz MI (2013) Discontinuous foci of cancer in a single core of prostatic biopsy: when it occurs and performance of quantification methods in a private-practice setting. Am J Surg Pathol 37:1831–1836
24. Epstein JI (2010) An update of the Gleason grading system. J Urol 183:433–440
25. Simon RM, Paik S, Hayes DF (2009) Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446–1452